Cargando…

Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status

BACKGROUND: A stepwise surgical approach with hemithyroidectomy and completion thyroidectomy was used to achieve definite characterization of follicular thyroid carcinoma (FTC). Choosing appropriate candidates for completion thyroidectomy has been controversial. OBJECTIVE: The aim of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hyunju, Heo, Jung, Ki, Chang-Seok, Shin, Jung Hee, Oh, Young Lyun, Son, Young Ik, Kim, Jee Soo, Kim, Sun Wook, Chung, Jae Hoon, Kim, Tae Yong, Kim, Tae Hyuk, Kim, Jung-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838536/
https://www.ncbi.nlm.nih.gov/pubmed/36637642
http://dx.doi.org/10.1245/s10434-022-13089-5
_version_ 1784869309620682752
author Park, Hyunju
Heo, Jung
Ki, Chang-Seok
Shin, Jung Hee
Oh, Young Lyun
Son, Young Ik
Kim, Jee Soo
Kim, Sun Wook
Chung, Jae Hoon
Kim, Tae Yong
Kim, Tae Hyuk
Kim, Jung-Han
author_facet Park, Hyunju
Heo, Jung
Ki, Chang-Seok
Shin, Jung Hee
Oh, Young Lyun
Son, Young Ik
Kim, Jee Soo
Kim, Sun Wook
Chung, Jae Hoon
Kim, Tae Yong
Kim, Tae Hyuk
Kim, Jung-Han
author_sort Park, Hyunju
collection PubMed
description BACKGROUND: A stepwise surgical approach with hemithyroidectomy and completion thyroidectomy was used to achieve definite characterization of follicular thyroid carcinoma (FTC). Choosing appropriate candidates for completion thyroidectomy has been controversial. OBJECTIVE: The aim of this study was to clarify the selection criteria for completion thyroidectomy using telomerase reverse transcriptase (TERT) promoter mutation. METHODS: A total of 87 FTC patients who had information about TERT promoter mutation from August 1995 to November 2020 were investigated. The cumulative risk of initial distant metastasis, disease recurrence, and cancer-specific death according to primary tumor size in each of the World Health Organization (WHO) 2017 classifications were calculated. RESULTS: Of the 87 patients, 8 (9.2%) had initial distant metastasis and 15 (17.2%) had persistent disease or developed structural recurrence. The threshold diameter for initial distant metastasis, disease recurrence, and cancer-specific death was 2 cm in minimally invasive FTC (MI-FTC) with mutant TERT (M-TERT) and in encapsulated angioinvasive FTC (EA-FTC) with M-TERT, while that in MI-FTC with wild-type TERT (WT-TERT) and EA-FTC with WT-TERT was 4 cm. The cumulative risk of initial distant metastasis, disease recurrence, and cancer-specific death according to primary tumor size in each WHO 2017 classification was significantly different only in patients with WT-TERT (p = 0.001, p = 0.019, and p = 0.005, respectively). CONCLUSIONS: The data suggest 2 cm as a critical threshold diameter for performance of completion thyroidectomy in MI-FTC with M-TERT and EA-FTC with M-TERT. TERT promoter mutational status can help select candidates for completion thyroidectomy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-13089-5.
format Online
Article
Text
id pubmed-9838536
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-98385362023-01-17 Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status Park, Hyunju Heo, Jung Ki, Chang-Seok Shin, Jung Hee Oh, Young Lyun Son, Young Ik Kim, Jee Soo Kim, Sun Wook Chung, Jae Hoon Kim, Tae Yong Kim, Tae Hyuk Kim, Jung-Han Ann Surg Oncol Endocrine Tumors BACKGROUND: A stepwise surgical approach with hemithyroidectomy and completion thyroidectomy was used to achieve definite characterization of follicular thyroid carcinoma (FTC). Choosing appropriate candidates for completion thyroidectomy has been controversial. OBJECTIVE: The aim of this study was to clarify the selection criteria for completion thyroidectomy using telomerase reverse transcriptase (TERT) promoter mutation. METHODS: A total of 87 FTC patients who had information about TERT promoter mutation from August 1995 to November 2020 were investigated. The cumulative risk of initial distant metastasis, disease recurrence, and cancer-specific death according to primary tumor size in each of the World Health Organization (WHO) 2017 classifications were calculated. RESULTS: Of the 87 patients, 8 (9.2%) had initial distant metastasis and 15 (17.2%) had persistent disease or developed structural recurrence. The threshold diameter for initial distant metastasis, disease recurrence, and cancer-specific death was 2 cm in minimally invasive FTC (MI-FTC) with mutant TERT (M-TERT) and in encapsulated angioinvasive FTC (EA-FTC) with M-TERT, while that in MI-FTC with wild-type TERT (WT-TERT) and EA-FTC with WT-TERT was 4 cm. The cumulative risk of initial distant metastasis, disease recurrence, and cancer-specific death according to primary tumor size in each WHO 2017 classification was significantly different only in patients with WT-TERT (p = 0.001, p = 0.019, and p = 0.005, respectively). CONCLUSIONS: The data suggest 2 cm as a critical threshold diameter for performance of completion thyroidectomy in MI-FTC with M-TERT and EA-FTC with M-TERT. TERT promoter mutational status can help select candidates for completion thyroidectomy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-13089-5. Springer International Publishing 2023-01-13 2023 /pmc/articles/PMC9838536/ /pubmed/36637642 http://dx.doi.org/10.1245/s10434-022-13089-5 Text en © Society of Surgical Oncology 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Endocrine Tumors
Park, Hyunju
Heo, Jung
Ki, Chang-Seok
Shin, Jung Hee
Oh, Young Lyun
Son, Young Ik
Kim, Jee Soo
Kim, Sun Wook
Chung, Jae Hoon
Kim, Tae Yong
Kim, Tae Hyuk
Kim, Jung-Han
Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status
title Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status
title_full Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status
title_fullStr Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status
title_full_unstemmed Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status
title_short Selection Criteria for Completion Thyroidectomy in Follicular Thyroid Carcinoma Using Primary Tumor Size and TERT Promoter Mutational Status
title_sort selection criteria for completion thyroidectomy in follicular thyroid carcinoma using primary tumor size and tert promoter mutational status
topic Endocrine Tumors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9838536/
https://www.ncbi.nlm.nih.gov/pubmed/36637642
http://dx.doi.org/10.1245/s10434-022-13089-5
work_keys_str_mv AT parkhyunju selectioncriteriaforcompletionthyroidectomyinfollicularthyroidcarcinomausingprimarytumorsizeandtertpromotermutationalstatus
AT heojung selectioncriteriaforcompletionthyroidectomyinfollicularthyroidcarcinomausingprimarytumorsizeandtertpromotermutationalstatus
AT kichangseok selectioncriteriaforcompletionthyroidectomyinfollicularthyroidcarcinomausingprimarytumorsizeandtertpromotermutationalstatus
AT shinjunghee selectioncriteriaforcompletionthyroidectomyinfollicularthyroidcarcinomausingprimarytumorsizeandtertpromotermutationalstatus
AT ohyounglyun selectioncriteriaforcompletionthyroidectomyinfollicularthyroidcarcinomausingprimarytumorsizeandtertpromotermutationalstatus
AT sonyoungik selectioncriteriaforcompletionthyroidectomyinfollicularthyroidcarcinomausingprimarytumorsizeandtertpromotermutationalstatus
AT kimjeesoo selectioncriteriaforcompletionthyroidectomyinfollicularthyroidcarcinomausingprimarytumorsizeandtertpromotermutationalstatus
AT kimsunwook selectioncriteriaforcompletionthyroidectomyinfollicularthyroidcarcinomausingprimarytumorsizeandtertpromotermutationalstatus
AT chungjaehoon selectioncriteriaforcompletionthyroidectomyinfollicularthyroidcarcinomausingprimarytumorsizeandtertpromotermutationalstatus
AT kimtaeyong selectioncriteriaforcompletionthyroidectomyinfollicularthyroidcarcinomausingprimarytumorsizeandtertpromotermutationalstatus
AT kimtaehyuk selectioncriteriaforcompletionthyroidectomyinfollicularthyroidcarcinomausingprimarytumorsizeandtertpromotermutationalstatus
AT kimjunghan selectioncriteriaforcompletionthyroidectomyinfollicularthyroidcarcinomausingprimarytumorsizeandtertpromotermutationalstatus